This clinical trial is focused on studying the effects of a treatment for lupus nephritis, a condition where the immune system attacks the kidneys, causing inflammation and damage. The treatment being tested is called ianalumab, also known by its code name VAY736. This study is an extension of a previous study, and it aims to evaluate the safety and effectiveness of continuing or stopping the treatment in participants who have already completed the initial study.

Participants in this study will receive ianalumab through a solution for injection. The study will observe the participants over a period to see if there are any changes in their condition, such as a return of kidney problems or the need to increase other medications that suppress the immune system. The study will also monitor for any side effects or health changes that may occur during the treatment period.

In addition to ianalumab, the study involves other medications that participants may have been taking, such as mycophenolate mofetil, tenofovir alafenamide, emtricitabine, tenofovir disoproxil, and entecavir. These medications are typically used to manage immune system activity and viral infections. The study will help determine the best approach to managing lupus nephritis in the long term, either by continuing the treatment or by safely withdrawing it.